AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21252240 — intervention group
Group type: COMPARATOR
Intervention: Incretin hormone responses
Number of subjects: 8
Study 21252248 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated PCOS
Number of subjects: 74
Study 21252248 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 74
Study 21253319 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX (adjuvant folinic acid/fluorouracil plus oxaliplatin)
Number of subjects: 366
Study 21253319 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine plus oxaliplatin)
Number of subjects: 366
Study 21253319 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall chemotherapy (FOLFOX and XELOX)
Number of subjects: 366
Study 21253319 — intervention group
Group type: COMPARATOR
Intervention: Age ≥55 years
Number of subjects: 366
Study 21253319 — intervention group
Group type: COMPARATOR
Intervention: Stage II or III
Number of subjects: 366
Study 21253319 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant setting
Number of subjects: 366
Study 21253319 — intervention group
Group type: COMPARATOR
Intervention: Performance status of 0
Number of subjects: 366
Study 21253319 — intervention group
Group type: COMPARATOR
Intervention: No prior chemotherapy
Number of subjects: 366
Study 21255443 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic and therapeutic cardiac catheterization
Number of subjects: 300
Study 21255443 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and hypertension (risk factors)
Number of subjects: 300
Study 21255766 — intervention group
Group type: EXPERIMENTAL
Intervention: Any antidepressant
Number of subjects: 947
Study 21255766 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-level antidepressant dose and duration
Number of subjects: 947
Study 21255766 — intervention group
Group type: EXPERIMENTAL
Intervention: Any psychotherapy
Number of subjects: 947
Study 21255766 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-level psychotherapy
Number of subjects: 947
Study 21255766 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonergic antidepressants and individual psychotherapy
Number of subjects: 947
Study 21255766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health treatment
Number of subjects: 947
Study 21256189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT-6 combined with the adjuvant IC31(®), administered at 0 and 2 months
Number of subjects: 0
Study 21256189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT-6 combined with the adjuvant IC31(®)
Number of subjects: 0
Study 21262599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous malignant melanomas (CMM)
Number of subjects: 30
Study 21262599 — intervention group
Group type: COMPARATOR
Intervention: Benign melanocytic nevi (BMN)
Number of subjects: 30
Study 21262599 — intervention group
Group type: COMPARATOR
Intervention: Dysplastic melanocytic nevi (DMN)
Number of subjects: 30
Study 21262916 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/pemetrexed therapy
Number of subjects: 126
Study 21262916 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher tertile of TS mRNA expression
Number of subjects: 126
Study 21262916 — intervention group
Group type: EXPERIMENTAL
Intervention: TS mRNA level and TS H-score
Number of subjects: 126
Study 21262916 — intervention group
Group type: COMPARATOR
Intervention: ERCC1 protein expression, TS and ERCC1 polymorphisms
Number of subjects: 126
Study 21262992 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 3670
Study 21263104 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 28384
Study 21263104 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroalbuminuria
Number of subjects: 28384
Study 21263104 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline albuminuria (microalbuminuria)
Number of subjects: 28384
Study 21263104 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline albuminuria (macroalbuminuria)
Number of subjects: 28384
Study 21263104 — intervention group
Group type: EXPERIMENTAL
Intervention: New microalbuminuria
Number of subjects: 28384
Study 21263104 — intervention group
Group type: EXPERIMENTAL
Intervention: New macroalbuminuria
Number of subjects: 28384
Study 21263104 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline macroalbuminuria treated with ACE inhibitor/ARB
Number of subjects: 28384
Study 21266211 — intervention group
Group type: EXPERIMENTAL
Intervention: POTS patients
Number of subjects: 38
Study 21266211 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study 21267044 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour intravenous patient-controlled analgesia (IV-PCA) with oxymorphone
Number of subjects: 12
Study 21267531 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation with capecitabine (825 mg/m² twice a day on radiotherapy days; weeks 1-4) and oxaliplatin (50 mg/m² intravenously on days 1, 8, 15, and 22) with radiotherapy (total dose 45 Gy)
Number of subjects: 59
Study 21267960 — intervention group
Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitors (88%)
Number of subjects: 822
Study 21267960 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (77%)
Number of subjects: 822
Study 21267960 — intervention group
Group type: EXPERIMENTAL
Intervention: Both converting enzyme inhibitors and beta-blockers (60%)
Number of subjects: 822
Study 21267960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular hospitalisation
Number of subjects: 822
Study 21267960 — intervention group
Group type: EXPERIMENTAL
Intervention: Unscheduled surgery visits
Number of subjects: 822
Study 21269431 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV)
Number of subjects: 141
Study 21269431 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher TSH levels
Number of subjects: 141
Study 21269431 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH, nulliparity, frank breech, placenta anterior
Number of subjects: 141
Study 21269835 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-limb support quintiles
Number of subjects: 125
Study 21270268 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)-monomethyl-L-arginine (L-NMMA)
Number of subjects: 84
Study 21270271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 1116
Study 21270271 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 1116
Study 21271599 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 17
Study 21273144 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation drug-eluting balloons (DEB) including SeQuent Please, In.Pact Falcon, New Dior, Pantera Lux
Number of subjects: 14
Study 21273144 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation drug-eluting balloons (DEB)
Number of subjects: 14
Study 21273196 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic repositioning
Number of subjects: 228
Study 21273196 — intervention group
Group type: COMPARATOR
Intervention: Standard LVtip to LVring configuration
Number of subjects: 228
Study 21273196 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative configurations
Number of subjects: 228
Study 21273493 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro with rHuPH20
Number of subjects: 22
Study 21273493 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular human insulin (RHI) with rHuPH20
Number of subjects: 22
Study 21273493 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro without rHuPH20
Number of subjects: 22
Study 21273493 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (RHI) without rHuPH20
Number of subjects: 22
Study 21273497 — intervention group
Group type: EXPERIMENTAL
Intervention: Vietnamese American patients with clinical depression (CES-D score ≥ 22)
Number of subjects: 1209
Study 21273497 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexican American patients with clinical depression (CES-D score ≥ 22)
Number of subjects: 1209
Study 21273497 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic white patients with clinical depression (CES-D score ≥ 22)
Number of subjects: 1209
Study 21273497 — intervention group
Group type: EXPERIMENTAL
Intervention: Vietnamese and Mexican patients with high depressive symptoms
Number of subjects: 1209
Study 21273497 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority patients with low levels of trust in their provider
Number of subjects: 1209
Study 21273938 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent, inactivated influenza vaccine (TIV), 2 doses
Number of subjects: 41
Study 21273938 — intervention group
Group type: COMPARATOR
Intervention: Control group (FT infants)
Number of subjects: 41
Study 21274359 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal lifestyle intervention (11 group sessions and weekly fitness training for 5 months)
Number of subjects: 50
Study 21274359 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 50
Study 21274364 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patches (4.6 mg/24 h)
Number of subjects: 0
Study 21274364 — intervention group
Group type: COMPARATOR
Intervention: Donepezil (5 to 10 mg/d)
Number of subjects: 0
Study 21276128 — intervention group
Group type: EXPERIMENTAL
Intervention: PEM-guided biopsy
Number of subjects: 19
Study 21276234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated whole abdominal radiotherapy (WAR)
Number of subjects: 37
Study 21277098 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide + Radiotherapy (RT)
Number of subjects: 24
Study 21277098 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) only
Number of subjects: 24
Study 21277691 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy focused extracorporeal shockwave therapy
Number of subjects: 566
Study 21278138 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) with unblinded use after 4 weeks
Number of subjects: 60
Study 21279689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (CMRI)
Number of subjects: 20
Study 21280008 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroRNA expression profiles from patients with SS
Number of subjects: 0
Study 21280008 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time quantitative polymerase chain reaction validation of microRNA
Number of subjects: 0
Study 21280008 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroRNA from patients with preserved or low salivary flow
Number of subjects: 0
Study 21280008 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted biologic targets of microRNA associated with inflammation or salivary gland dysfunction
Number of subjects: 0
Study 21281234 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-ELISA- and Aspergillus PCR-driven antifungal therapy
Number of subjects: 0
Study 21281234 — intervention group
Group type: COMPARATOR
Intervention: Standard fever-driven empiric antifungal treatment strategy
Number of subjects: 0
Study 21281486 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time RT-PCR assay for EpCAM detection in peripheral blood preoperatively and postoperatively (D1B, D7B, 6WB)
Number of subjects: 58
Study 21281486 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time RT-PCR assay for EpCAM detection in peritoneal lavage fluid preoperatively and postoperatively
Number of subjects: 58
Study 21281521 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting ≥ 1 dietary, sedentary, or PA recommendations
Number of subjects: 92
Study 21281521 — intervention group
Group type: COMPARATOR
Intervention: Not meeting any behavioral recommendations
Number of subjects: 92
Study 21281873 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT)
Number of subjects: 20
Study 21281873 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched and sex-matched)
Number of subjects: 20
Study 21282185 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection drug use
Number of subjects: 163
Study 21282185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual transmission
Number of subjects: 163
Study 21282185 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV identical strain clusters
Number of subjects: 163
Study 21282185 — intervention group
Group type: EXPERIMENTAL
Intervention: Men who have sex with men
Number of subjects: 163
Study 21282484 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PAH (REVEAL)
Number of subjects: 2141
Study 21282484 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of patients with idiopathic PAH and those with PAH associated with drugs and toxins
Number of subjects: 2141
Study 21282484 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of patients with PAH associated with congenital heart disease, connective tissue disease, and human immunodeficiency virus
Number of subjects: 2141
Study 21282484 — intervention group
Group type: COMPARATOR
Intervention: NHANES normal comparison group
Number of subjects: 2141
Study 21282578 — intervention group
Group type: COMPARATOR
Intervention: Electroretinogram (ERG) pattern responses, b-wave in the scotopic bright flash ERG, a-wave and b-wave in the photopic single-flash ERG, oscillatory potential responses
Number of subjects: 28
Study 21282578 — intervention group
Group type: COMPARATOR
Intervention: Vascular response to flicker light
Number of subjects: 28
Study 21282578 — intervention group
Group type: EXPERIMENTAL
Intervention: Flicker light-induced arterial retinal vasodilation
Number of subjects: 28
Study 21282578 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural and neurovascular dysfunctions
Number of subjects: 28
Study 21283743 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory abnormalities based on non-indigenous laboratory references
Number of subjects: 281
Study 21283743 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abnormalities
Number of subjects: 281
Study 21283743 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory reference intervals developed from East and Southern Africa
Number of subjects: 281
Study 21283743 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible participants
Number of subjects: 281
Study 21284479 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring with microdialysis-based subcutaneous glucose monitoring system
Number of subjects: 20
Study 21284837 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery or lifestyle intervention (specifics not provided)
Number of subjects: 133
Study 21284880 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian C-Spine Rule
Number of subjects: 3000
Study 21285134 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant CAPOX (capecitabine-oxaliplatin) plus bevacizumab
Number of subjects: 46
Study 21287306 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida spp. in respiratory tract cultures
Number of subjects: 100
Study 21287306 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial pathogens in respiratory tract cultures
Number of subjects: 100
Study 21287306 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture negative
Number of subjects: 100
Study 21287306 — intervention group
Group type: COMPARATOR
Intervention: Control group with no clinical suspicion of VAP
Number of subjects: 100
Study 21288612 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplement (WPS) 60 g/day for 4 weeks
Number of subjects: 11
Study 21289257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral water load
Number of subjects: 20
Study 21289257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 3% saline
Number of subjects: 20
Study 21289257 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 20
Study 21289257 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of vasopressin and copeptin concentrations
Number of subjects: 20
Study 21289257 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma osmolality with copeptin
Number of subjects: 20
Study 21289257 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma osmolality with vasopressin
Number of subjects: 20
Study 21289369 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (second line treatment)
Number of subjects: 51
Study 21292087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal microdialysis (MD)
Number of subjects: 12
Study 21292758 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwhite patients
Number of subjects: 3138
Study 21292991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level exercise (30 W) in LVSD patients
Number of subjects: 60
Study 21293089 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg daily for 4 weeks, with an option to increase to 10 mg at week 4 (both studies) and week 8 (VOLT)
Number of subjects: 2645
Study 21293089 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine extended release 4 mg for ≥ 4 weeks prior to solifenacin
Number of subjects: 2645
Study 21293089 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 2645
Study 21293986 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard drug use (cocaine, amphetamines, or heroin)
Number of subjects: 643
Study 21294601 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 551
Study 21296274 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) as salvage treatment after prostatic radiotherapy
Number of subjects: 0
Study 21296274 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 0
Study 21296508 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release zolpidem
Number of subjects: 20
Study 21296508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21296811 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanted active epiretinal array
Number of subjects: 1
Study 21296811 — intervention group
Group type: EXPERIMENTAL
Intervention: Retina underlying the array
Number of subjects: 1
Study 21296811 — intervention group
Group type: COMPARATOR
Intervention: Normal patients (control group)
Number of subjects: 1
Study 21296824 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Awareness and Eccentric Viewing (module 1)
Number of subjects: 30
Study 21296824 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of Reading Eye Movements (module 2)
Number of subjects: 30
Study 21296824 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading Practice with Sequential Presentation of Lexical Information (module 3)
Number of subjects: 30
Study 21296824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 30
Study 21298520 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid VATS sleeve lobectomy
Number of subjects: 148
Study 21299393 — intervention group
Group type: EXPERIMENTAL
Intervention: BD GGBP sensor (intradermal placement)
Number of subjects: 40
Study 21299393 — intervention group
Group type: EXPERIMENTAL
Intervention: BD GGBP sensor (subcutaneous placement)
Number of subjects: 40
Study 21299393 — intervention group
Group type: COMPARATOR
Intervention: GOx-based sensor
Number of subjects: 40
Study 21299393 — intervention group
Group type: EXPERIMENTAL
Intervention: BD GGBP sensor
Number of subjects: 40
Study 21299450 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating pathology class
Number of subjects: 125
Study 21299450 — intervention group
Group type: EXPERIMENTAL
Intervention: Low psychopathology class
Number of subjects: 125
Study 21299450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate psychopathology class
Number of subjects: 125
Study 21299922 — intervention group
Group type: EXPERIMENTAL
Intervention: Sino-Nasal Outcome Test 22 (SNOT-22) initial test
Number of subjects: 40
Study 21299922 — intervention group
Group type: EXPERIMENTAL
Intervention: Sino-Nasal Outcome Test 22 (SNOT-22) retest
Number of subjects: 40
Study 21299922 — intervention group
Group type: EXPERIMENTAL
Intervention: Sino-Nasal Outcome Test 22 (SNOT-22) initial test and retest scores
Number of subjects: 40
Study 21299922 — intervention group
Group type: EXPERIMENTAL
Intervention: Sino-Nasal Outcome Test 22 (SNOT-22) items
Number of subjects: 40
Study 21299922 — intervention group
Group type: EXPERIMENTAL
Intervention: Sino-Nasal Outcome Test 22 (SNOT-22) subscales
Number of subjects: 40
Study 21300307 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (BAT) using an implanted device (Rheos)
Number of subjects: 0
Study 21300307 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 21300462 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron neutron capture therapy (BNCT)
Number of subjects: 30
Study 21300566 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted HIV-1 vaccine candidate
Number of subjects: 50
Study 21300566 — intervention group
Group type: EXPERIMENTAL
Intervention: Elecsys HIV Combi assay
Number of subjects: 50
Study 21300566 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVIA Centaur EHIV
Number of subjects: 50
Study 21300566 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM HIV O Plus assay
Number of subjects: 50
Study 21300924 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vorinostat (200 mg twice daily on days 1-14 of a 21-day cycle)
Number of subjects: 35
Study 21300924 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vorinostat
Number of subjects: 35
Study 21301463 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-contrast ultrasound
Number of subjects: 0
Study 21304070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasmall superparamagnetic particles of iron oxide (USPIO) administered before and 24 to 36 hours after MRI imaging
Number of subjects: 29
Study 21304070 — intervention group
Group type: COMPARATOR
Intervention: No USPIO uptake
Number of subjects: 29
Study 21304070 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific USPIO uptake
Number of subjects: 29
Study 21304982 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted pH1N1 vaccine (Focetria®, Novartis) administered twice
Number of subjects: 58
Study 21304982 — intervention group
Group type: EXPERIMENTAL
Intervention: 2009-2010 seasonal TIV
Number of subjects: 58
Study 21306210 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory and neuroendocrine biomarkers
Number of subjects: 0